{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:52:05Z","timestamp":1788587525664,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Japanese Ministry of Health, Labour and Welfare","award":["H23-\u5b9f\u7528\u5316(\u81e8\u5e8a)-\u6307\u5b9a-005"],"award-info":[{"award-number":["H23-\u5b9f\u7528\u5316(\u81e8\u5e8a)-\u6307\u5b9a-005"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP15lk0103004"],"award-info":[{"award-number":["JP15lk0103004"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","award":["Only treatment drugs were provided"],"award-info":[{"award-number":["Only treatment drugs were provided"]}],"id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1136\/annrheumdis-2018-213920","type":"journal-article","created":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T12:15:34Z","timestamp":1538482534000},"page":"1720-1729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":174,"title":["Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial"],"prefix":"10.1016","volume":"77","author":[{"given":"Yuko","family":"Kaneko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0574-9611","authenticated-orcid":false,"given":"Kei","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonoti","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyota","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2018-213920_bib1","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.berh.2016.08.003","article-title":"Adult-onset Still's disease: Advances in the treatment","volume":"30","author":"Casta\u00f1eda","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213920_bib2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/14397595.2014.973659","article-title":"The effect of tocilizumab on preventing relapses in adult-onset Still's disease: A retrospective, single-center study","volume":"25","author":"Nishina","year":"2015","journal-title":"Mod Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213920_bib3","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1136\/ard.2005.042945","article-title":"Refractory adult onset Still's disease and hypersensitivity to non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2inhibitors:are biological agents the solution?","volume":"64","author":"Aarntzen","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2018-213920_bib4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/ard.56.2.144","article-title":"Methotrexate treatment in patients with adult onset Still's disease\u2013retrospective study of 13 Japanese cases","volume":"56","author":"Fujii","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2018-213920_bib5","first-page":"373","article-title":"Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease","volume":"26","author":"Fautrel","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213920_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.semarthrit.2007.04.002","article-title":"Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokinemeasurementsand a review of the literature","volume":"37","author":"K\u00f6tter","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2018-213920_bib7","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/ard.2009.108068","article-title":"IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still'sdisease","volume":"69","author":"Naumann","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2018-213920_bib8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/s10165-011-0477-9","article-title":"Adult-onset Still's disease with macrophage activation syndrome successfully treated with a combination of methotrexateandetanercept","volume":"22","author":"Maeshima","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213920_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10067-013-2381-5","article-title":"Tocilizumab for the treatment of adult-onset Still's disease: results from a case series","volume":"33","author":"Cipriani","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213920_bib10","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3109\/s10165-011-0569-6","article-title":"Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan","volume":"22","author":"Suematsu","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213920_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000036","article-title":"Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remissionona first, second or third biological agent","volume":"1","author":"Woerner","year":"2015","journal-title":"RMD Open"},{"key":"10.1136\/annrheumdis-2018-213920_bib12","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/annrheumdis-2012-202310","article-title":"Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extensionstudyin Japan","volume":"72","author":"Yokota","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2018-213920_bib13","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind,placebo-controlled,withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2018-213920_bib14","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2018-213920_bib15","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinrainpatients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2018-213920_bib16","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2018-213920_bib17","first-page":"424","article-title":"Preliminary criteria for classification of adult Still's disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213920_bib18","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/art.30238","article-title":"Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis","volume":"63","author":"Vojinovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2018-213920_bib19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2018-213920_bib20","unstructured":"European Medicines Agency,2009.ICH Topic E 2 A: clinical safety data management: definitions and standards for expedited reporting. Availablefrom:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002749.pdf."},{"key":"10.1136\/annrheumdis-2018-213920_bib21","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/rheumatology\/keu019","article-title":"Fulminant myocarditis and macrophage activation syndrome secondary to adult-onset Still's disease successfully treatedwithtocilizumab","volume":"53","author":"Savage","year":"2014","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2018-213920_bib22","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s10067-010-1418-2","article-title":"Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated withtocilizumab","volume":"29","author":"Sumida","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213920_bib23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3899\/jrheum.130881","article-title":"Tocilizumab in adult-onset Still's disease: the Israeli experience","volume":"41","author":"Elkayam","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213920_bib24","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/art.38398","article-title":"Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospectiveopen-labelstudy of thirty-four patients","volume":"66","author":"Ortiz-Sanju\u00e1n","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213920_bib25","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jbspin.2013.12.011","article-title":"Canakinumab in a case of adult onset still's disease: efficacy only on systemic manifestations","volume":"81","author":"Lo Gullo","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1136\/annrheumdis-2018-213920_bib26","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/annrheumdis-2013-204137","article-title":"Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritistreatedwith tocilizumab: implications for molecular targeted therapy","volume":"73","author":"Nishina","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2018-213920_bib27","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.autrev.2014.08.032","article-title":"Adult onset Still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions","volume":"13","author":"Maria","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1136\/annrheumdis-2018-213920_bib28","first-page":"2189","article-title":"Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onsetStill'sdisease","volume":"31","author":"Chen","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213920_bib29","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/rheumatology\/40.12.1398","article-title":"Cytokine and immunogenetic profiles in Japanese patients with adult still's disease. association with chronic articular disease","volume":"40","author":"Fujii","year":"2001","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2018-213920_bib30","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/acr.22194","article-title":"Clinical manifestations of Adult-onset Still's disease presenting with erosive arthritis: Association with low levelsofferritin and Interleukin-18","volume":"66","author":"Ichida","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1136\/annrheumdis-2018-213920_bib31","first-page":"2422","article-title":"Serum cytokine profiles in patients with adult onset Still's disease","volume":"30","author":"Choi","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213920_bib32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clim.2016.05.010","article-title":"Cytokine profile in adult-onset Still's disease: Comparison with systemic juvenile idiopathic arthritis","volume":"169","author":"Inoue","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1136\/annrheumdis-2018-213920_bib33","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.3899\/jrheum.100247","article-title":"Clinical manifestations but not cytokine profiles differentiate adult-onset Still's disease and sepsis","volume":"37","author":"Rau","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213920_bib34","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/ard.2004.024026","article-title":"Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases","volume":"64","author":"Fautrel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2018-213920_bib35","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","volume":"67","author":"Lequerr\u00e9","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2018-213920_bib36","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.3899\/jrheum.111549","article-title":"Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized,multicenterstudy","volume":"39","author":"Nordstr\u00f6m","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213920_bib37","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ncprheum0338","article-title":"Interleukin 6: from bench to bedside","volume":"2","author":"Nishimoto","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213920_bib38","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/art.38042","article-title":"Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis","volume":"65","author":"Lovell","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2018-213920_bib39","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemicjuvenileidiopathic arthritis","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213920_bib40","doi-asserted-by":"crossref","DOI":"10.1007\/s13554-012-0001-6","article-title":"Treatment of systemic juvenile idiopathic arthritis with tocilizumab - the role of anti-interleukin-6 therapy afteradecade of treatment","volume":"2","author":"Reiff","year":"2012","journal-title":"Biol Ther"},{"key":"10.1136\/annrheumdis-2018-213920_bib41","first-page":"125","article-title":"Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition","volume":"8","author":"Grevich","year":"2017","journal-title":"Adolesc Health Med Ther"},{"key":"10.1136\/annrheumdis-2018-213920_bib42","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724023094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724023094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2018-213920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T02:17:55Z","timestamp":1736043475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724023094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0003496724023094"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2018-213920","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2018-213920","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 \u00a9 Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}